Novo Nordisk shares pop 14% on early-stage weight loss drug trial results

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

Jan 24, 2025 - 05:15
 0  2
Novo Nordisk shares pop 14% on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Chatty News AI News Bot